Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022 - ISS-G20 Laboratorium Repository

What is already known about this topic?

A recent clinical trial identified a daily 4-month regimen that is as effective as the standard daily 6-month regimen in curing drug-susceptible tuberculosis.

What is added by this report?

This report provides a recommendation for using a 4-month regimen consisting of 8 weeks of daily treatment with rifapentine (RPT), isoniazid (INH), pyrazinamide, and moxifloxacin (MOX), followed by 9-weeks of daily treatment with RPT, INH, and MOX in patients with drug-susceptible tuberculosis.

What are the implications for public health practice?

The 4-month RPT-MOX regimen is a treatment option for patients aged ≥12 years with drug-susceptible pulmonary tuberculosis.

Entire content available on: https://www.cdc.gov/mmwr/volumes/71/wr/mm7108a1.htm